Not really. When performing clinical trials, if you'd like to use the results of the studies in chinese/indian populations you'll need to prove bioequivalence in many cases, so you're going to need to collect a meaningful sample in the first place.

The reality is that most clinical trials aren't successes. If you can get a huge cohort of people for relatively cheap elsewhere, you can screen a lot of promising but doomed tests at a cheaper price point, then only re-create similar testing on the most promising candidates in your lucrative markets.